Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology

Radek Pudil, Christian Mueller, Jelena Čelutkienė, Peter A. Henriksen, Dan Lenihan, Susan Dent, Ana Barac, Susanna Stanway, Javid Moslehi, Thomas M. Suter, Bonnie Ky, Martin Štěrba, Daniela Cardinale, Alain Cohen-Solal, Carlo Gabriele Tocchetti, Dimitrios Farmakis, Jutta Bergler-Klein, Markus S. Anker, Stephan Von Haehling, Yury Belenkov, Zaza Iakobishvili, Christoph Maack, Fortunato Ciardiello, Frank Ruschitzka, Andrew J.S. Coats, Petar Seferovic, Mitja Lainscak, Massimo F. Piepoli, Ovidiu Chioncel, Jereon Bax, Jean-Sebastien Hulot, Hadi Skouri, Eva Simona Hägler-Laube, Riccardo Asteggiano, Teresa Lopez Fernandez, Rudolf A. de Boer, Alexander R. Lyon

Open source

DOI: 10.1002/ejhf.2017
Published: 2020-10-20
Container: European Journal of Heart Failure
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ejhf.2017,
  title = {Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology},
  author = {Radek Pudil and Christian Mueller and Jelena Čelutkienė and Peter A. Henriksen and Dan Lenihan and Susan Dent and Ana Barac and Susanna Stanway and Javid Moslehi and Thomas M. Suter and Bonnie Ky and Martin Štěrba and Daniela Cardinale and Alain Cohen-Solal and Carlo Gabriele Tocchetti and Dimitrios Farmakis and Jutta Bergler-Klein and Markus S. Anker and Stephan Von Haehling and Yury Belenkov and Zaza Iakobishvili and Christoph Maack and Fortunato Ciardiello and Frank Ruschitzka and Andrew J.S. Coats and Petar Seferovic and Mitja Lainscak and Massimo F. Piepoli and Ovidiu Chioncel and Jereon Bax and Jean-Sebastien Hulot and Hadi Skouri and Eva Simona Hägler-Laube and Riccardo Asteggiano and Teresa Lopez Fernandez and Rudolf A. de Boer and Alexander R. Lyon},
  year = {2020},
  journal = {European Journal of Heart Failure},
  doi = {10.1002/ejhf.2017},
  url = {https://doi.org/10.1002/ejhf.2017}
}

RIS

TY  - JOUR
TI  - Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology
AU  - Radek Pudil
AU  - Christian Mueller
AU  - Jelena Čelutkienė
AU  - Peter A. Henriksen
AU  - Dan Lenihan
AU  - Susan Dent
AU  - Ana Barac
AU  - Susanna Stanway
AU  - Javid Moslehi
AU  - Thomas M. Suter
AU  - Bonnie Ky
AU  - Martin Štěrba
AU  - Daniela Cardinale
AU  - Alain Cohen-Solal
AU  - Carlo Gabriele Tocchetti
AU  - Dimitrios Farmakis
AU  - Jutta Bergler-Klein
AU  - Markus S. Anker
AU  - Stephan Von Haehling
AU  - Yury Belenkov
AU  - Zaza Iakobishvili
AU  - Christoph Maack
AU  - Fortunato Ciardiello
AU  - Frank Ruschitzka
AU  - Andrew J.S. Coats
AU  - Petar Seferovic
AU  - Mitja Lainscak
AU  - Massimo F. Piepoli
AU  - Ovidiu Chioncel
AU  - Jereon Bax
AU  - Jean-Sebastien Hulot
AU  - Hadi Skouri
AU  - Eva Simona Hägler-Laube
AU  - Riccardo Asteggiano
AU  - Teresa Lopez Fernandez
AU  - Rudolf A. de Boer
AU  - Alexander R. Lyon
PY  - 2020
JO  - European Journal of Heart Failure
DO  - 10.1002/ejhf.2017
UR  - https://doi.org/10.1002/ejhf.2017
ER  -

APA

Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T. M., Ky, B., Štěrba, M., Cardinale, D., Cohen-Solal, A., Tocchetti, C. G., Farmakis, D., Bergler-Klein, J., Anker, M. S., Haehling, S. V., Belenkov, Y., Iakobishvili, Z., Maack, C., Ciardiello, F., Ruschitzka, F., Coats, A. J., Seferovic, P., Lainscak, M., Piepoli, M. F., Chioncel, O., Bax, J., Hulot, J., Skouri, H., Hägler-Laube, E. S., Asteggiano, R., Fernandez, T. L., Boer, R. A. D., & Lyon, A. R. (2020). Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2017

Source records

crossref · retrieved 2026-09-26T19:30:25.527Z